Protective Role of the Biofield Energy Treated Test Formulation on Vital Organs Function using Cell-Based Assays

Dublin Core

Title

Protective Role of the Biofield Energy Treated Test Formulation on Vital Organs Function using Cell-Based Assays

Subject

Organ Health

Description

Dysfunction of vital organs is the main concern for human health. Therefore, it is necessary to homeostat the normal function of vital organs such as lungs, liver, brain and heart for better health. The aim of this study was to evaluate the effect of the Consciousness Energy Healing Treated test formulation on the function of vital organs in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Thomas Charles Slade, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the tested formulation was safe and non-toxic in nature in six different cells. The experimental groups like the untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI) and BT-Med + BT-TI groups showed 74.4% (at 10 µg/mL) and 73.7% (at 1 µg/mL) restoration of cell viability, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI and BT-Med + BT-TI groups showed 76.4% (at 10 µg/mL) and 87.5% (at 1 µg/mL) restoration of cell viability, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 209.5%, 757.8% and 836.2% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively, at 1 µg/mL compared to the untreated. Alkaline phosphatase (ALP) level was significantly increased by 71.7%, 71.9% and 56.7% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively in human bone osteosarcoma cells (MG-63) at 50 µg/mL compared to the untreated. Additionally, the level of ALP was also significantly increased by 124.9% and 106.3% in the BT-Med + BT-TI group at 25 and 50 µg/mL, respectively in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 88.3% and 75.5% in the BT-Med + BT-TI group at 1 and 10 µg/mL, respectively; while 82.8% (at 0.1 µg/mL) in the UT-Med + BT-TI group as compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 47.5%, 79.8% and 94% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 1 µg/mL compared to the untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 67.4%, 60.8% and 80.7% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10 µg/mL; while 137% (at 0.1 µg/mL) in the BT-Med + BT-TI group as compared to the untreated group. Serotonin level was significantly increased by 225.7% (at 1 µg/mL), 176.1% (at 25 µg/mL) and 175.7% (at 63 µg/mL) in the BT-Med + BT-TI group; while 317.9% (at 1 µg/mL) in the UT-Med + BT-TI group as compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 195.3% (at 1 µg/mL), 176.2% (at 10 µg/mL) and 194.7% (at 50 µg/mL) in the BT-Med + BT-TI group compared to the untreated group in MG-63 cells. Altogether data suggest that these results suggest that Biofield Energy Treated test formulation significantly protect the major organs viz. bones, heart, liver, lungs and brain and also improved their functions. Therefore, The Biofield Energy Treatment (The Trivedi Effect®) can be used as a complementary and alternative therapy against several disorders such as heart attack, heart failure, coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, Wilson disease, asthma, pneumonia, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.

Creator

Thomas Charles Slade, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana

Publisher

SciTech Central Inc.

Date

July 21, 2019

Contributor

[no text]

Rights

[no text]

Relation

[no text]

Format

[no text]

Language

English

Type

Journal Article

Identifier

[no text]

Coverage

[no text]

Files

TH-136-Mahendra-Trivedi-Protective-Role-of-the-Biofield-Energy-Treated-Test-Formulation-on-Vital-Organs-Function-using-Cell-Based-Assays.pdf

Citation

Thomas Charles Slade, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana , “Protective Role of the Biofield Energy Treated Test Formulation on Vital Organs Function using Cell-Based Assays,” Mahendra Trivedi, accessed March 28, 2024, https://mahendratrivedi.omeka.net/items/show/429.